Kynam Capital Management, LP
Source: SEC Form 13F · as of Mar 2026Kynam Capital Management, LP holds 24 biotech & pharma companies tracked by BioSniper, totaling $1.04B in value as of Mar 2026 (SEC Form 13F).
Companies held
24
Total value held
$1.04B
BioSniper AIPage evidence connected
Prepared research question
What matters most for Celldex Therapeutics, Inc. (CLDX)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| CLDXCelldex Therapeutics, Inc. | 5,840,567 | $185.3M |
| PCVXVaxcyte, Inc. | 2,922,335 | $169.8M |
| COGTCogent Biosciences, Inc. | 4,037,331 | $155.4M |
| BEAMBeam Therapeutics Inc. | 3,682,185 | $87.7M |
| CTMXCytomX Therapeutics, Inc. | 15,013,093 | $70.6M |
| TVTXTravere Therapeutics, Inc. | 1,569,018 | $46.6M |
| VRDNViridian Therapeutics, Inc.\DE | 2,341,652 | $45.8M |
| CGEMCullinan Therapeutics, Inc. | 3,114,132 | $44.3M |
| KALVKalVista Pharmaceuticals, Inc. | 1,820,954 | $36.7M |
| APLSApellis Pharmaceuticals, Inc. | 825,000 | $33.2M |
| IMCRImmunocore Holdings plc | 884,937 | $26.7M |
| STROSUTRO BIOPHARMA, INC. | 872,558 | $21.7M |
| SLNOSOLENO THERAPEUTICS INC | 560,000 | $18.7M |
| NRIXNurix Therapeutics, Inc. | 1,194,757 | $18.5M |
| PHVSPharvaris N.V. | 640,395 | $18.1M |
| RLAYRelay Therapeutics, Inc. | 1,424,259 | $14.2M |
| GERNGERON CORP | 6,836,318 | $10.2M |
| DSGNDesign Therapeutics, Inc. | 784,606 | $8.3M |
| CLYMClimb Bio, Inc. | 1,003,341 | $6.9M |
| BHVNBiohaven Ltd. | 702,884 | $5.9M |
| PRLDPrelude Therapeutics Inc | 1,592,551 | $5.4M |
| ALECAlector, Inc. | 2,000,000 | $4.3M |
| PRQRProQR Therapeutics N.V. | 1,566,317 | $2.5M |
| CADLCandel Therapeutics, Inc. | 200,000 | $980K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.